Figure 2.

Network plots for 4-week healing rate. (a) Main analysis. (b) Sensitivity analysis. (c) Subgroup analysis on patients without severe baseline grade. (d) Subgroup analysis on patients with severe baseline grade.

Eso40, Esomeprazole 40 mg qd; Fex40, Fexuprazan 20 mg qd; Ila10, Ilaprazole 10 mg qd; Kev20, Keverprazan 20 mg qd; Lan30, Lansoprazole 30 mg qd; Lan60, Lansoprazole 60 mg qd; Ome 40, Omeprazole 40 mg qd; Ome 20, Omeprazole 20 mg qd; Pan40, Pantoprazole 40 mg qd; Rab10, Rabeprazole 10 mg bid; Rab20, Rabeprazole 20 mg qd; Teg100, Tegoprazan 100 mg qd; Teg50, Tegoprazan 50 mg qd; Vpz20, Vonoprazan 20 mg qd; Vpz40, Vonoprazan 40 mg qd.